Par Health

Par Health Recalls 22 Argatroban Lots Over Particulate Matter

Image
Par Health Recalls 22 Argatroban Lots Over Particulate Matter

Rochester, Mich. – October 14, 2026 -- Par Health is recalling 22 lots of Argatroban Injection 250 mg/2.5 mL (100 mg/mL) to the hospital/user level after detecting particulate matter in certain lots.

Particulates include cellulose, plastics and stopper material

The company identified the contaminants as cellulose, polystyrene, polyethylene terephthalate, stopper material, and possibly stainless steel. Par Health states that administering product containing particulate matter has a reasonable probability of causing life-threatening adverse health consequences.

The listed risks are pulmonary emboli, occlusions of other blood vessels that can lead to tissue death and possible organ damage, and inflammation of vein walls that may lead to clotting. To date, Par Health has received no reports of adverse events related to the recall.

Par Health Recalls Two Dexmedetomidine Lots Over Particulate Risk

Image
Par Health Recalls Two Dexmedetomidine Lots Over Particulate Risk

Rochester, Mich. – September 21, 2026 -- Par Health is voluntarily recalling two lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection 400 mcg/100 mL (4 mcg/mL) at the hospital level after detecting particulate matter identified as cellulose or stopper material.

Contaminated vials carry risk of pulmonary emboli and vessel occlusion

The FDA-notified recall covers Lots 87558 and 88802, which were distributed nationwide to wholesalers between September 21, 2026 and September 21, 2026. Par Health warned that administering the affected product carries a reasonable probability of causing life-threatening adverse health consequences, including pulmonary emboli, occlusions of other blood vessels that can lead to tissue death and organ damage, and inflammation of vein walls that may result in clotting. The company said it has not received any adverse event reports tied to the recall to date.